AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02130284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Management Feature in Insulin pump
Description: All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
Study NCT01160874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography
Description: Sleep study monitoring
Study NCT01160874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Sleep study monitoring
Study NCT01160874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maintenance Wakefulness Test
Description: Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
Study NCT01160874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance Wakefulness Test
Description: Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
Study NCT01160874 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological evaluation
Description: Neuropsychological evaluation for cognitive functions study
Study NCT01160874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: Neuropsychological evaluation for cognitive functions study
Study NCT01160874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Driving test on a simulator
Description: Driving simulator test during wich a camera register different parameters as the position of the vehicle.
Study NCT01160874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving test on a simulator
Description: Driving simulator test during wich a camera register different parameters as the position of the vehicle.
Study NCT01802684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
Study NCT03758365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study NCT03758365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desonide 0.05% Cream
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study NCT03758365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study NCT00721019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-hour bedtime
Description: 10 days with sleep restricted only to a 5-hour bedtime period at night
Study NCT00721019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8.5-hour bedtimes
Description: 10 days with sleep allowed only during a 8.5-hour period at night
Study NCT02623829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: 50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
Study NCT02623829 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 1ml of normal saline will be administered
Study NCT02103088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual and urological intervention
Description: Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
Study NCT02414880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
Study NCT02414880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
Study NCT02414880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
Study NCT01530815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine Infusion
Description: Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
Study NCT02711956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Study NCT02711956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02081521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community behaviour change campaign
Description: Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
Study NCT04740021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: 10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
Study NCT04740021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.
Study NCT04740021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.
Study NCT01681680 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Subjects will be given an oral dose of metformin once per day for two days.
Study NCT06264102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece.
Study NCT02337439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Information Processing Training
Description: Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
Study NCT02337439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Training
Description: Commercially available educational software
Study NCT03687684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 Tablets.
Study NCT03604835 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
Study NCT02519829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl closure
Description: Total Hip Arthroplasty with monocryl closure of wound
Study NCT02519829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl and Staple closure
Description: Total Hip Arthroplasty with vicryl and staple closure of wound
Study NCT02519829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm dressing
Description: Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
Study NCT02519829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze dressing
Description: Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
Study NCT02259556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART30
Description: Cells will be infused 1 day after the completion of conditioning regimen.
Study NCT01276782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levothyroxine
Description: It is FDA approved drug for thyroid disease
Study NCT02334059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion plus placebo infusion of normal saline
Study NCT02334059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine plus magnesium
Description: Ketamine plus magnesium infusion
Study NCT02334059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 placebo infusions
Study NCT02334059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo infusions
Study NCT02470039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
Study NCT02470039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
Study NCT02470039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered once daily
Study NCT02470039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Administered once daily
Study NCT00176904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
Study NCT00176904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, Antithymocyte Globulin
Description: Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients > 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Study NCT02381821 — intervention group
Intervention type: OTHER
Intervention: 3 D ultrasound and Doppler examination
Description: Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis
Study NCT02381821 — intervention group
Intervention type: DRUG
Intervention: GnRH agonist
Description: All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
Study NCT00006156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No injection of FSH
Study NCT00006156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: FSH
Description: FSH Stimulation Test
Study NCT03463356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shame Intervention
Description: In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
Study NCT03654456 — intervention group
Intervention type: BIOLOGICAL
Intervention: OSA
Description: The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
Study NCT00721877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: Given orally
Study NCT00721877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00721877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04017013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia
Description: The epidural infusion will be as follows:~* Isobaric Bupivacaine 0.5% 40 cc~* Morphine 4 mg (1 ampoule up to 10 cc and 4 cc of the mixture will be applied)~* Saline solution 0.9% 156 cc.~* Total Volume: 200 cc.~This mixture will be prepared by a nurse outside the research group outside the operating room once indicated.~The infusion will be scheduled at 7 cc / hour per continuous infusion set and will be connected to the epidural catheter after its placement.
Study NCT04017013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Infusion
Description: 2% Lidocaine IV without epinephrine: 1 mg/kg/ hour for up to 24 hours, started immediately after anesthetic induction.
Study NCT02275364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test strip
Description: Class I device for the application to the nose to facilitate better air flow through the nose
Study NCT02275364 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo strip
Description: Placebo strip
Study NCT02275364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal spray
Description: Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
Study NCT02275364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal spray
Description: Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
Study NCT05541302 — intervention group
Intervention type: DEVICE
Intervention: TMS
Description: Transcranial Magnetic Stimulation
Study NCT02681302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
Study NCT02681302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
Study NCT02010632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel product Apolets®
Description: * Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7
Study NCT02010632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original clopidogrel product Plavix®
Description: * Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7
Study NCT00070135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00070135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT00070135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT00070135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00070135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00070135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given PO or IV
Study NCT00070135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplantation
Study NCT00652938 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Vaccine (GSK580299) Cervarix TM
Description: IM administration
Study NCT00652938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine (GSK580299) Cervarix TM
Description: IM administration
Study NCT00652938 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: IM administration
Study NCT01038115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation
Description: Comparison of three different techniques for pulmonary vein isolation
Study NCT04473690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose of KBP-COVID-19
Description: Low Dose of KBP-COVID-19 and adjuvant
Study NCT04473690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose of KBP-COVID-19
Description: High Dose of KBP-COVID-19 and adjuvant
Study NCT04473690 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffered saline solution
Study NCT01082562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-844421
Description: Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days
Study NCT01082562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride injection solution
Description: Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days
Study NCT01653171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water (Placebo)
Description: Water 100 mL
Study NCT03916744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
Study NCT03916744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Breast cancer surgery will take place on Day 15 (+/-2 days).
Study NCT02676596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-312 10 mg QD
Study NCT02676596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-312 25 mg QD
Study NCT02676596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-312 50 mg QD
Study NCT02676596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-312 100 mg QD
Study NCT02676596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-312 200 mg QD
Study NCT02676596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-312 400 mg QD
Study NCT02676596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT02890537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core decompression/PREOB® implantation
Description: All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
Study NCT02890537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Core decompression/BMC implantation
Description: All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
Study NCT00661661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg BID up to 10 mg BID until launch
Study NCT04095039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Patients in both arms will undergo hemodialysis to remove phosphate from the blood; however, patients in the Hi Arm will only be titrated down to no lower than 6.5mg/dl